Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050581 · ClinicalTrials.gov registry record
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 72
- Enrollment target
NCT02050581: Clinical Trial study, sponsored by Weill Medical College of Cornell University.
NCT02050581 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02050581 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 72 participants
- Enrollment target
Study Summary
In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators will also evaluate observed toxicities of the combination, and characteristics associated with response.
Primary Outcome
An increase in Platelet count after 8 weeks on treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-01 |
Why NCT02050581 stopped before completion
NCT02050581 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02050581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02050581 about?
NCT02050581 is a clinical study titled "A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone". In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators wi...
What is the current status of trial NCT02050581?
This trial is currently terminated. The enrollment target is 72 participants. The study started on 2011-01.
Who is sponsoring clinical trial NCT02050581?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia